Found: 16
Select item for more details and to access through your institution.
Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and Safety of Once-Daily Extended-Release ( ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain.
- Published in:
- Pain Practice, 2017, v. 17, n. 3, p. 382, doi. 10.1111/papr.12462
- By:
- Publication type:
- Article
A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression.
- Published in:
- Pain Practice, 2016, v. 16, n. 4, p. 473, doi. 10.1111/papr.12298
- By:
- Publication type:
- Article
Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials.
- Published in:
- Pain Practice, 2016, v. 16, n. 3, p. 345, doi. 10.1111/papr.12281
- By:
- Publication type:
- Article
P4‐389: ELENBECESTAT, E2609, A BACE INHIBITOR: RESULTS FROM A PHASE‐2 STUDY IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT AND MILD‐TO‐MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1623, doi. 10.1016/j.jalz.2018.07.213
- By:
- Publication type:
- Article
AN EVALUATION OF THE SAFETY OF NELOTANSERIN, A HIGHLY POTENT AND SELECTIVE 5-HT2A INVERSE AGONIST THAT IS BEING DEVELOPED AS A TREATMENT FOR VISUAL HALLUCINATIONS AND REM BEHAVIOR DISORDER IN LEWY BODY DEMENTIA.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P824, doi. 10.1016/j.jalz.2016.06.1675
- By:
- Publication type:
- Article
Poster 151 Evaluation of the Effectiveness of Once‐Daily Hydrocodone in Patient Subgroups.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2015, v. 7, p. S141, doi. 10.1016/j.pmrj.2015.06.189
- By:
- Publication type:
- Article
Poster 151 Evaluation of the Effectiveness of Once-Daily Hydrocodone in Patient Subgroups.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2015, v. 7, p. S141, doi. 10.1016/j.pmrj.2015.06.189
- By:
- Publication type:
- Article
Poster 46 The Adverse Event Profile of Buprenorphine Transdermal Delivery System in Patients ≥65 and <65 Years of Age
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Poster 45 Survey of Treatment Satisfaction With Buprenorphine Transdermal Delivery System
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Poster 46 The Adverse Event Profile of Buprenorphine Transdermal Delivery System in Patients ≥65 and <65 Years of Age.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2011, v. 3, p. S192, doi. 10.1016/j.pmrj.2011.08.102
- By:
- Publication type:
- Article
Poster 45 Survey of Treatment Satisfaction With Buprenorphine Transdermal Delivery System.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2011, v. 3, p. S192, doi. 10.1016/j.pmrj.2011.08.101
- By:
- Publication type:
- Article
Poster 46 The Adverse Event Profile of Buprenorphine Transdermal Delivery System in Patients ≥65 and <65 Years of Age.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Poster 45 Survey of Treatment Satisfaction With Buprenorphine Transdermal Delivery System.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Apheleia‐001: A novel prescreening study designed to enrich and accelerate Alzheimer's disease clinical trials by efficiently identifying trial‐eligible participants determined to have a high probability of study inclusion, including amyloid positivity
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.074277
- By:
- Publication type:
- Article
Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.054331
- By:
- Publication type:
- Article